The core activity of Pharmact AG is the development and application of innovative medical solutions, particularly in the areas of atherosclerosis, diabetes mellitus, and severe liver diseases. The company develops genetically optimized enzymes and point-of-care tests (POCT) for the diagnosis and treatment of diseases, such as familial hypercholesterolemia. The core activity also includes research and development of new therapies and prevention products, as well as the commercial marketing of these products.